tiprankstipranks
Sectra AB Class B (SE:SECT.B)
:SECT.B

Sectra AB Class B (SECT.B) AI Stock Analysis

3 Followers

Top Page

SE:SECT.B

Sectra AB Class B

(SECT.B)

Select Model
Select Model
Select Model
Neutral 67 (OpenAI - 5.2)
Rating:67Neutral
Price Target:
kr255.00
▲(1.84% Upside)
Action:ReiteratedDate:03/07/26
The score is primarily supported by strong financial performance (rapid TTM growth, strong margins, and very low leverage with robust ROE). It is held back by a mixed-to-weak technical trend (negative MACD and below longer-term moving averages) and especially by expensive valuation (very high P/E and low yield).
Positive Factors
Revenue Growth
A ~129% TTM revenue acceleration signals sustained commercial traction and successful product adoption across imaging and security lines. Durable multi-year contracts and platform sales imply recurring revenue and expansion opportunities that support predictable top-line growth over months to years.
Negative Factors
Margin Variability
Material year-to-year swings in gross profit and margins point to variability in product mix, contract timing, or pricing pressure. That uneven profitability complicates forecasting and could erode investor confidence if high margins prove inconsistent over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A ~129% TTM revenue acceleration signals sustained commercial traction and successful product adoption across imaging and security lines. Durable multi-year contracts and platform sales imply recurring revenue and expansion opportunities that support predictable top-line growth over months to years.
Read all positive factors

Sectra AB Class B (SECT.B) vs. iShares MSCI Sweden ETF (EWD)

Sectra AB Class B Business Overview & Revenue Model

Company Description
Sectra AB Class B (SECT.B) is a Swedish company specializing in medical technology and cybersecurity solutions. It operates primarily in the healthcare sector, offering products and services that enhance medical imaging, radiology, and pathology. ...
How the Company Makes Money
Sectra primarily makes money through two main business areas: medical imaging IT and secure communications/cybersecurity. In medical imaging, it generates revenue by licensing and delivering software platforms (e.g., PACS/RIS and enterprise imagin...

Sectra AB Class B Financial Statement Overview

Summary
Strong financial profile with sharply accelerating TTM revenue (+~129%), solid profitability (operating margin ~24%, net margin ~19%), and a conservatively levered balance sheet (debt-to-equity ~0.05) supporting strong ROE (low-30% range). Score is tempered by notable margin variability across years and uneven cash-flow conversion, including a TTM free-cash-flow decline (~-18%) despite good FCF-to-net-income (~0.92x).
Income Statement
88
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
80
Positive
BreakdownTTMApr 2024Apr 2023Apr 2022Apr 2021Apr 2020
Income Statement
Total Revenue3.42B3.24B2.96B2.35B1.95B1.63B
Gross Profit1.87B543.41M557.55M488.91M1.71B1.48B
EBITDA784.05M795.35M615.06M538.55M477.28M429.01M
Net Income537.49M563.37M428.39M374.96M314.79M275.51M
Balance Sheet
Total Assets4.05B3.76B3.21B2.74B2.19B1.65B
Cash, Cash Equivalents and Short-Term Investments1.35B1.34B804.64M945.24M808.77M454.85M
Total Debt109.51M87.46M31.79M82.26M62.62M73.45M
Total Liabilities2.12B1.84B1.64B1.44B1.11B756.33M
Stockholders Equity1.93B1.92B1.57B1.30B1.08B895.62M
Cash Flow
Free Cash Flow727.41M812.37M75.58M347.70M542.55M304.53M
Operating Cash Flow799.99M922.36M326.33M440.49M616.92M372.19M
Investing Cash Flow-136.29M-113.86M-130.74M-212.79M-68.35M-66.82M
Financing Cash Flow-448.49M-251.88M-222.20M-219.29M-198.75M-198.69M

Sectra AB Class B Technical Analysis

Technical Analysis Sentiment
Positive
Last Price250.40
Price Trends
50DMA
209.62
Positive
100DMA
234.49
Positive
200DMA
282.04
Negative
Market Momentum
MACD
7.25
Negative
RSI
61.37
Neutral
STOCH
75.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECT.B, the sentiment is Positive. The current price of 250.4 is above the 20-day moving average (MA) of 228.20, above the 50-day MA of 209.62, and below the 200-day MA of 282.04, indicating a neutral trend. The MACD of 7.25 indicates Negative momentum. The RSI at 61.37 is Neutral, neither overbought nor oversold. The STOCH value of 75.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SECT.B.

Sectra AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
kr3.60B24.4917.89%1.61%1.53%0.79%
67
Neutral
kr46.09B68.3827.98%0.43%10.08%68.12%
60
Neutral
kr8.32B233.591.20%8.39%-85.36%
57
Neutral
kr52.15B17.166.91%2.16%6.74%21.40%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
kr13.10B-0.873.34%0.80%-1.29%
48
Neutral
kr1.28B-1.36-50.36%-23.24%45.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SECT.B
Sectra AB Class B
235.20
-15.38
-6.14%
SE:GETI.B
Getinge
191.95
7.05
3.82%
SE:VITR
Vitrolife AB
96.70
-54.09
-35.87%
SE:BICO
BICO Group AB Class B
18.08
-17.40
-49.04%
SE:CEVI
CellaVision AB
151.00
0.71
0.47%
SE:XVIVO
Xvivo Perfusion AB
264.00
-5.60
-2.08%

Sectra AB Class B Corporate Events

Sectra boosts cloud-driven recurring revenue as orders surge in nine-month 2025/2026 report
Mar 6, 2026
Sectra reported strong demand in its nine-month 2025/2026 interim period, highlighted by a 4.2% increase in contracted order bookings to SEK 6.05 billion and an 18.5% rise in recurring revenue, driven by a 57.5% surge in cloud recurring revenue. N...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 07, 2026